Tower Research Capital LLC TRC Lowers Stake in Progyny, Inc. (NASDAQ:PGNY)

Tower Research Capital LLC TRC lowered its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 58.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 16,850 shares of the company's stock after selling 23,625 shares during the period. Tower Research Capital LLC TRC's holdings in Progyny were worth $291,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Thematics Asset Management raised its holdings in Progyny by 3.1% during the 4th quarter. Thematics Asset Management now owns 112,486 shares of the company's stock valued at $1,940,000 after buying an additional 3,336 shares during the last quarter. MetLife Investment Management LLC grew its position in shares of Progyny by 6.3% in the 4th quarter. MetLife Investment Management LLC now owns 51,891 shares of the company's stock worth $895,000 after buying an additional 3,085 shares during the last quarter. Natixis bought a new stake in Progyny in the fourth quarter valued at $69,000. Dimensional Fund Advisors LP increased its position in shares of Progyny by 6.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,186,027 shares of the company's stock valued at $20,458,000 after buying an additional 74,740 shares during the period. Finally, First Trust Advisors LP grew its stake in Progyny by 13.1% in the fourth quarter. First Trust Advisors LP now owns 24,105 shares of the company's stock worth $416,000 after purchasing an additional 2,794 shares during the period. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Trading Down 0.4 %

PGNY traded down $0.09 during mid-day trading on Thursday, hitting $23.33. 185,162 shares of the stock were exchanged, compared to its average volume of 1,737,429. The company has a market cap of $2.00 billion, a PE ratio of 40.22, a PEG ratio of 2.39 and a beta of 1.37. The firm's fifty day moving average is $21.93 and its two-hundred day moving average is $19.43. Progyny, Inc. has a 1-year low of $13.39 and a 1-year high of $32.99.

Analyst Upgrades and Downgrades

Several research firms have issued reports on PGNY. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a report on Tuesday, January 28th. Bank of America raised their price objective on Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price target on the stock in a research note on Monday, March 31st. Finally, Canaccord Genuity Group upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a research note on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Progyny has an average rating of "Hold" and a consensus target price of $23.64.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.